Trends in Cardiovascular Medicine
Volume 15, Issue 3 , Pages 92-96 , April 2005

Caveolae, Lipid Rafts, and Vascular Disease

  • Xiang-An Li
    • ,
  • William V. Everson
    • ,
  • Eric J. Smart

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Eric J. Smart, PhD, Department of Pediatrics, University of Kentucky, 423 Sanders-Brown, 800 Limestone St, Lexington, KY 40536-0230, USA. Tel.: (+1) 859-323-6412; fax: (+1) 859-257-2120.

References 

  1. Anderson RG. The caveolae membrane system. Annu Rev Biochem. 1998;67:199–225
  2. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science. 2002;296:1821–1825
  3. Brown D, Waneck GL. Glycosyl–phosphatidylinositol-anchored membrane proteins. J Am Soc Nephrol. 1992;3:895–906
  4. Bucci M, Gratton JP, Rudic RD, et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med. 2000;6:1362–1367
  5. Cao G, Yang G, Timme TL, et al. Disruption of the caveolin-1 gene impairs renal calcium reabsorption and leads to hypercalciuria and urolithiasis. Am J Pathol. 2003;162:1241–1248
  6. Chang WJ, Rothberg KG, Kamen BA, Anderson RG. Lowering the cholesterol content of MA104 cells inhibits receptor-mediated transport of folate. J Cell Biol. 1992;118:63–69
  7. Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 2001;293:2449–2452
  8. Fielding PE, Fielding CJ. Plasma membrane caveolae mediate the efflux of cellular free cholesterol. Biochemistry. 1995;34:14288–14292
  9. Frank PG, Lee H, Park DS, et al. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:98–105
  10. Fu Y, Hoang A, Escher G, et al. Expression of caveolin-1 enhances cholesterol efflux in hepatic cells. J Biol Chem. 2004;279:14140–14146
  11. Galbiati F, Engelman JA, Volonté D, et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin–glycoprotein complex, and t-tubule abnormalities. J Biol Chem. 2001;276:21425–21433
  12. Garcia-Cardena G, Martasek P, Masters BS, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the NOS caveolin binding domain in vivo. J Biol Chem. 1997;272:25437–25440
  13. Garcia-Cardena G, Oh P, Liu J, et al. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci USA. 1996;93:6448–6453
  14. Ghosh S, Gachhui R, Crooks C, et al. Interaction between caveolin-1 and the reductase domain of endothelial nitric-oxide synthase. Consequences for catalysis. J Biol Chem. 1998;273:22267–22271
  15. Glenney JR. The sequence of human caveolin reveals identity with VIP21, a component of transport vesicles. FEBS Lett. 1992;314:45–48
  16. Glenney JR, Soppet D. Sequence and expression of caveolin, a protein component of caveolae plasma membrane domains phosphorylated on tyrosine in Rous sarcoma virus–transformed fibroblasts. Proc Natl Acad Sci USA. 1992;89:10517–10521
  17. Goldstein JL, Brown MS, Anderson RG, et al. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol. 1985;1:1–39
  18. Gong MC, Wilson ME, Kelly T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI–dependent manner. J Clin Invest. 2003;111:1579–1587
  19. Gratton JP, Bernatchez P, Sessa WC. Caveolae and caveolins in the cardiovascular system. Circ Res. 2004;94:1408–1417
  20. Hagiwara Y, Sasaoka T, Araishi K, et al. Caveolin-3 deficiency causes muscle degeneration in mice. Hum Mol Genet. 2000;9:3047–3054
  21. Ju H, Zou R, Venema VJ. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem. 1997;272:18522–18525
  22. Knowles JW, Reddick RL, Jennette JC, et al. Enhanced atherosclerosis and kidney dysfunction in eNOS (−/−)Apoe(−/−) mice are ameliorated by enalapril treatment. J Clin Invest. 2000;105:451–458
  23. Krieger M. Charting the fate of the “good cholesterol”: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. 1999;68:523–558
  24. Kuhlencordt PJ, Gyurko R, Han F, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001;104:448–454
  25. Kurzchalia TV, Dupree P, Parton RG, et al. VIP21, a 21-kD membrane protein is an integral component of trans-Golgi-network–derived transport vesicles. J Cell Biol. 1992;118:1003–1014
  26. Li X-A, Titlow WB, Jackson BA, et al. High-density lipoprotein binding to scavenger receptor class B, type I activates endothelial nitric oxide synthase in a ceramide-dependent manner. J Biol Chem. 2002;277:11058–11063
  27. Liu J, Garcia-Cardena G, Sessa WC. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulate release of nitric oxide: implications for caveolae localization. Biochemistry. 1996;35:13277–13281
  28. Michel JB, Feron O, Sacks D, et al. Reciprocal regulation of endothelial nitric-oxide synthase by Ca2+-calmodulin and caveolin. J Biol Chem. 1997;272:15583–15586
  29. Michel JB, Feron O, Sase K, et al. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem. 1997;272:25907–25912
  30. Mineo C, Yuhanna IS, Quon MJ, et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278:9142–9149
  31. Murata M, Peranen J, Schreiner R, et al. VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA. 1995;92:10339–10343
  32. Park DS, Woodman SE, Schubert W, et al. Caveolin 1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Path. 2002;160:2207–2217
  33. Pike LJ, Han X, Chung KN, et al. Lipid rafts are enriched in enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry. 2002;41:2075–2088
  34. Razani B, Engelman JA, Wang XB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem. 2001;276:38121–38138
  35. Razani B, Wang XB, Engelman JA, et al. Caveolin-2 deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Biol Cell. 2002;22:2329–2344
  36. Rothberg KG, Heuser JE, Donzell WC, et al. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68:673–682
  37. Rothberg KG, Ying Y, Kamen BA, et al. Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J Cell Biol. 1990;111:2931–2938
  38. Sessa WC. Atheroprotection in the absence of “caves”: is it the fat, the vessels, or both?. Arterios Thromb Vasc Biol. 2004;24:4–6
  39. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol. 2002;64:749–774
  40. Shaul PW. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J Physiol. 2003;547:21–33
  41. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–572
  42. Smart EJ, Graf GA, McNiven MA, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol. 1999;19:7289–7304
  43. Trigatti B, Rigotti A, Krieger M. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Lipidol. 2000;11:123–131
  44. Uittenbogaard A, Everson WV, Matveev SV, et al. Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid–protein complex. J Biol Chem. 2002;277:4925–4931
  45. Uittenbogaard A, Shaul PW, Yuhanna IS, et al. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000;275:11278–11283
  46. Uittenbogaard A, Smart EJ. Palmitoylation of caveolin-1 is required for cholesterol binding, chaperone complex formation, and rapid transport of cholesterol to caveolae. J Biol Chem. 2000;275:25595–25599
  47. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol. 1955;1:445–458
  48. Yuhanna IS, Zhu Y, Cox BE, et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med. 2001;7:853–857
  49. Zhao YY, Liu Y, Stan RV, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci USA. 2002;99:11375–11380

PII: S1050-1738(05)00028-9

doi: 10.1016/j.tcm.2005.04.001

Trends in Cardiovascular Medicine
Volume 15, Issue 3 , Pages 92-96 , April 2005

Article Tools